<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">medsovet-536</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>БРОНХОПУЛЬМОНОЛОГИЯ, ЛОР</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BRONCHOPULMONOLOGY, ENT</subject></subj-group></article-categories><title-group><article-title>Карбоцистеина лизиновая соль в лечении больных хронической обструктивной болезнью легких с частыми обострениями</article-title><trans-title-group xml:lang="en"><trans-title>Carbocisteine lysine salt in the treatment of patients with chronic obstructive pulmonary disease with frequent exacerbations</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тыртов</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Tyrtov</surname><given-names>D. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шмелёв</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Shmelev</surname><given-names>E. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ «Городская клиническая больница №24 ДЗМ»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital № 24 of the Moscow City Health Department, Branch №1</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Центральный научно-исследовательский институт туберкулеза» РАМН, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central Tuberculosis Research Institute of RAMS, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2014</year></pub-date><volume>0</volume><issue>4</issue><fpage>8</fpage><lpage>11</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Тыртов Д.С., Шмелёв Е.И., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Тыртов Д.С., Шмелёв Е.И.</copyright-holder><copyright-holder xml:lang="en">Tyrtov D.S., Shmelev E.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/536">https://www.med-sovet.pro/jour/article/view/536</self-uri><abstract><p>В статье отражены результаты рандомизированного открытого сравнительного исследования эффективности применения карбоцистеина лизиновой соли у больных хронической обструктивной болезнью легких с частыми обострениями. Полученные данные свидетельствуют, что применение карбоцистеина лизиновой соли способствует улучшению качества мокроты (уменьшению гнойности и более легкой экспекторации), снижению потребности в бронходилататорах, повышению толерантности к физической нагрузке, снижению частоты, тяжести и продолжительности обострений.</p></abstract><trans-abstract xml:lang="en"><p>The article presents the results of a randomized, open, comparative study of the effect of carbocisteine lysine salt in patients with chronic obstructive pulmonary disease with frequent exacerbations. The results demonstrate that carbocisteine lysine salt facilitates sputum properties (decreased purulence and improved expectoration), reduces the need for bronchodilators, increases exercise tolerance, and reduces frequency, severity and duration of exacerbations.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая обструктивная болезнь легких с частыми обострениями</kwd><kwd>мукорегулирующие средства</kwd><kwd>карбоцистеина лизиновая соль</kwd><kwd>chronic obstructive pulmonary disease with frequent exacerbations</kwd><kwd>mucoregulating drugs</kwd><kwd>carbocisteine lysine salt</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
